Schedule 7 substances or pesticides
(section 172(4)(d))
Employer and employee to whom
notice relates
Amount of compensation for forfeited
thing (section 200)
Applicant
Giving compliance notice (section 201) Person who receives notice
Refusing to give authorisation
(section 243F(5))
Revocation of authorisation
(section 243F(7))
Medicines, Poisons and Therapeutic Goods Act 2012 166
1 KEY Key to abbreviations
amd = amended od = order
app = appendix om = omitted
bl = by-law pt = Part
ch = Chapter r = regulation/rule
cl = clause rem = remainder
div = Division renum = renumbered
exp = expires/expired rep = repealed
f = forms s = section
Gaz = Gazette sch = Schedule
hdg = heading sdiv = Subdivision
ins = inserted SL = Subordinate Legislation
lt = long title sub = substituted
nc = not commenced
2 LIST OF LEGISLATION
Medicines, Poisons and Therapeutic Goods Act 2012 (Act No. 13, 2012)
Assent date 27 April 2012
Commenced 1 May 2014 (Gaz S22, 30 April 2014, p 12)
Medicines, Poisons and Therapeutic Goods Amendment Act 2014 (Act No. 12, 2014)
Assent date 16 April 2014
Commenced 16 April 2014
Correctional Services (Related and Consequential Amendments) Act 2014 (Act No. 27,
2014)
Assent date 4 September 2014
Commenced 9 September 2014 (Gaz S80, 9 September 2014, p 2)
Statute Law Amendment (Directors' Liability) Act 2015 (Act No. 26, 2015)
Assent date 18 September 2015
Commenced 14 October 2015 (Gaz G41, 14 October 2015, p 3)
Local Court (Related Amendments) Act 2016 (Act No. 8, 2016)
Assent date 6 April 2016
Commenced 1 May 2016 (s 2, s 2 Local Court (Repeals and Related
Amendments) Act 2016 (Act No. 9, 2016) and Gaz S34,
29 April 2016)
Justice Legislation Amendment (Drug Offences) Act 2016 (Act No. 17, 2016)
Assent date 8 June 2016
Commenced s 17 (to ext ins new s 15): 10 October 2016;
rem: 18 July 2016 (Gaz S67, 18 July 2016)
Statute Law Revision Act 2017 (Act No. 4, 2017)
Assent date 10 March 2017
Commenced 12 April 2017 (Gaz G15, 12 April 2017, p 3)
Medicines, Poisons and Therapeutic Goods Act 2012 167
Health Practitioner Regulation (National Uniform Legislation) and Other Legislation
Amendment Act 2018 (Act No. 28, 2018)
Assent date 30 November 2018
Commenced 1 December 2018 (s 2)
Medical Services Amendment Act 2019 (Act No. 17, 2019)
Assent date 30 May 2019
Commenced 31 May 2019 (s 2)
Hemp Industry Act 2019 (Act No. 25, 2019)
Assent date 2 September 2019
Commenced 6 May 2020 (Gaz G18, 6 May 2020, p 2)
Statute Law Revision Act 2020 (Act No. 26, 2020)
Assent date 19 November 2020
Commenced 20 November 2020 (s 2)
Medicines, Poisons and Therapeutic Goods Amendment Act 2021 (Act No. 1, 2021)
Assent date 25 February 2021
Commenced 26 February 2021 (s 2)
Medicines, Poisons and Therapeutic Goods Legislation Amendment Act 2021 (Act
No. 27, 2021)
Assent date 15 December 2021
Commenced 16 December 2021 (s 2)
Medicines, Poisons and Therapeutic Goods Legislation Amendment Act 2022 (Act
No. 25, 2022)
Assent date 9 December 2022
Commenced 10 December 2022 (s 2)
Statute Law Revision and Repeals Act 2026 (Act No. 3, 2026)
Assent date 9 February 2026
Commenced 10 February 2026 (s 2)
3 GENERAL AMENDMENTS
General amendments of a formal nature (which are not referred to in the table
of amendments to this reprint) are made by the Interpretation Legislation
Amendment Act 2018 (Act No. 22, 2018) to: ss 1, 5, 19, 24, 32, 43, 44, 80,
89, 92, 121, 125, 127, 128, 129, 183, 207, 232, 251, 252, 283 and 293.
4 LIST OF AMENDMENTS
ss 3 – 4 amd No. 4, 2017, s 21
s 5 amd No. 12, 2014, s 3; No. 4, 2017, s 21; No. 28, 2018, s 12; No. 17, 2019,
s 14; No. 1, 2021, s 4; No. 27, 2021, s 4; No. 25, 2022, s 4
s 6 rep No. 4, 2017, s 20
s 7 amd No. 4, 2017, s 21
s 10 amd No. 25, 2022, s 5
s 11 rep No. 25, 2022, s 6
s 12 amd No. 4, 2017, s 21
s 13 rep No. 4, 2017, s 20
Schedule Sch 7 - Medicines, Poisons and Therapeutic Goods Act 2012 - substances or pesticides | Zoe
Medicines, Poisons and Therapeutic Goods Act 2012 168
ch 1
pt 1.2
div 2
sdiv 3 hdg amd No. 4, 2017, s 21
s 17 amd No. 4, 2017, s 21
s 19 amd No. 12, 2014, s 4
s 20 amd No. 4, 2017, s 21
s 21 amd No. 4, 2017, s 21; No. 25, 2022, s 7
s 22 amd No. 4, 2017, s 21
ch 1
pt 1.2
div 2
sdiv 4 hdg amd No. 4, 2017, s 21
s 23 amd No. 4, 2017, s 21
s 25 amd No. 25, 2022, s 8
s 26 amd No. 12, 2014, s 5
s 25 amd No. 28, 2018, s 12; No. 27, 2021, s 11
s 28 sub No. 12, 2014, s 6
amd No. 25, 2022, s 9
s 28A ins No. 12, 2014, s 6
sub No. 28, 2018, s 10
amd No. 25, 2022, s 10
s 31 amd No. 4, 2017, s 21
s 31A ins No. 25, 2019, s 46
ss 32 – 33 amd No. 4, 2017, s 21
ch 2 hdg amd No. 4, 2017, s 21
s 34 amd No. 12, 2014, s 7; No. 4, 2017, s 21
s 35 amd No. 12, 2014, s 8; No. 4, 2017, s 21
ch 2
pt 2.2 hdg amd No. 4, 2017, s 21
ss 37 – 38 sub No. 25, 2022, s 11
s 48 amd No. 25, 2022, s 12
s 57 amd No. 4, 2017, s 21; No. 27, 2021, s 11
s 59A ins No. 12, 2014, s 9
s 61 amd No. 25, 2022, s 54
s 62 sub No. 12, 2014, s 10
rep No. 25, 2022, s 13
ch 2
sdiv 3 hdg amd No. 25, 2022, s 54
s 63 sub No. 12, 2014, s 11; No. 25, 2022, s 14
s 64 amd No. 28, 2018, s 12
sub No. 25, 2022, s 14
s 65 amd No. 12, 2014, s 12
rep No. 25, 2022, s 14
s 67 amd No. 12, 2014, s 13
rep No. 25, 2022, s 15
ch 2
sdiv 3A hdg ins No. 25, 2022, s 16
s 70 rep No. 12, 2014, s 15
ins No. 25, 2022, s 16
ss 70A – 70D ins No. 25, 2022, s 16
Medicines, Poisons and Therapeutic Goods Act 2012 169
ch 2
sdiv 4 hdg amd No. 12, 2014, s 14
s 71 amd No. 12, 2014, s 16
sub No. 25, 2022, s 17
s 72 amd No. 12, 2014, s 17
sub No. 25, 2022, s 17
s 73 amd No. 4, 2017, s 21
s 75 sub No. 25, 2022, s 18
s 78 amd No. 25, 2022, s 19
ss 79 – 80 amd No. 4, 2017, s 21
s 81 amd No. 27, 2021, s 11
s 83 amd No. 27, 2021, s 11
s 84 amd No. 27, 2021, s 5; No. 25, 2022, s 20
s 86 amd No. 4, 2017, s 21
s 92 amd No. 12, 2014, s 18; No. 25, 2022, s 21
s 96 amd No. 27, 2021, s 6
pt 2.6 hdg amd No. 4, 2017, s 21
s. 98 amd No. 4, 2017, s 21
s 99 amd No. 12, 2014, s 19; No. 25, 2022, s 22
s 100 amd No. 12, 2014, s 20
sub No. 25, 2022, s 23
ch 2
pt 2.7 hdg amd No. 4, 2017, s 21
ss 101 – 105 amd No. 4, 2017, s 21
s 109 rep No. 12, 2014, s 21
s 110 amd No. 12, 2014, s 22; No. 3, 2026, s 43
ch 2
pt 2.7
div 4A hdg ins No. 25, 2022, s 24
ss 112A –
112C ins No. 25, 2022, s 24
s 113 amd No. 4, 2017, s 21
ch 3 hdg amd No. 4, 2017, s 21
s 117 amd No. 25, 2022, s 25
ss 118 – 119 amd No. 4, 2017, s 21
s 120 amd No. 25, 2022, s 26
s 121 amd No. 17, 2016, s 46; No. 4, 2017, s 21
s 122 amd No. 4, 2017, s 21
s 122A ins No. 25, 2022, s 27
s 123A ins No. 25, 2022, s 28
s 127 amd No. 17, 2016, s 46
s 128 amd No. 17, 2016, s 46; No. 25, 2022, s 29
s 129 amd No. 12, 2014, s 23; No. 17, 2016, s 46; No. 25, 2022, s 30
s 130 amd No. 25, 2022, s 31
s 131 amd No. 25, 2022, s 32
s 134 amd No. 4, 2017, s 21; No. 25, 2022, s 33
s 135 amd No. 4, 2017, s 21; No. 25, 2022, s 34
s 136 amd No. 4, 2017, s 21
s 136A ins No. 25, 2022, s 35
s 140 sub No. 25, 2022, s 36
s 141 and No. 25, 2022, s 37
ss 142 – 143 amd No. 4, 2017, s 21
s 144 amd No. 12, 2014, s 24; No. 4, 2017, s 21
s 145A ins No. 25, 2022, s 38
s 182 amd No. 8, 2016, s 45
s 193 amd No. 26, 2020, s 3
Medicines, Poisons and Therapeutic Goods Act 2012 170
s 203 amd No. 4, 2017, s 21
s 206 amd No. 4, 2017, s 21
s 207 sub No. 27, 2021, s 7
s 215 amd No. 26, 2015, s 75
s 219 amd No. 4, 2017, s 21
s 228 amd No. 3, 2026, s 44
s 230 amd No. 25, 2022, s 39
s 236 amd No. 3, 2026, s 45
ch 7
pt 7.1AA hdg ins No. 27, 2021, s 8
ch 7
div 1 hdg ins No. 27, 2021, s 8
ss 243A –
243B ins No. 27, 2021, s 8
ch 7
div 2 hdg ins No. 27, 2021, s 8
ss 243C –
243E ins No. 27, 2021, s 8
ch 7
div 3 hdg ins No. 27, 2021, s 8
ss 243F –
243G ins No. 27, 2021, s 8
ch 7
div 4 hdg ins No. 27, 2021, s 8
ss 243H –
243L ins No. 27, 2021, s 8
ch 7
div 5 hdg ins No. 27, 2021, s 8
ss 243M –
243Q ins No. 27, 2021, s 8
s 244 amd No. 25, 2022, s 40
ch 7
pt 7.2
div 1 hdg amd No. 4, 2017, s 21
s 245 amd No. 25, 2022, s 41
s 246 amd No. 25, 2022, s 42
ss 247 – 248 rep No. 25, 2022, s 43
s 249 amd No. 12, 2014, s 25
rep No. 25, 2022, s 43
s 250 amd No. 12, 2014, s 26; No. 28, 2018, s 12
rep No. 25, 2022, s 43
s 251 amd No. 4, 2017, s 21; No. 25, 2022, s 44
s 252 amd No. 27, 2014, s 57; No. 25, 2022, s 45
s 253 amd No. 25, 2022, s 46
s 254 amd No. 12, 2014, s 27; No. 28, 2018, s 11
sub No. 25, 2022, s 47
ch 7
pt 7.2
div 1A hdg ins No. 1, 2021, s 5
rep No. 25, 2022, s 48
ss 254A –
254C ins No. 1, 2021, s 5
rep No. 25, 2022, s 48
Medicines, Poisons and Therapeutic Goods Act 2012 171
s 257 amd No. 4, 2017, s 21; No. 25, 2022, s 49
s 261 amd No. 12, 2014, s 28
s 266 amd No. 25, 2022, s 50
s 268 amd No. 25, 2022, s 51
s 269 amd No. 25, 2022, s 52
s 279 amd No. 4, 2017, s 21
s 281 amd No. 12, 2014, s 29; No. 4, 2017, s 21
s 283 amd No. 12, 2014, s 30; No. 4, 2017, s 21
s 294 exp No. 13, 2012, s 294(5)
ch 9
pt 9.3 hdg ins No. 26, 2015, s 76
s 295 exp No. 13, 2012, s 305
ins No. 26, 2015, s 76
ch 9
pt 9.4 hdg ins No. 27, 2021, s 9
ss 296 – 298 exp No. 13, 2012, s 305
ins No. 27, 2021, s 9
ch 9
pt 9.5 hdg ins No. 25, 2022, s 53
ss 299 – 307 ins No. 25, 2022, s 53
ch 10 hdg exp No. 13, 2012, s 305
pt 10.1 hdg exp No. 13, 2012, s 305
ss 299 – 303 exp No. 13, 2012, s 305
pt 10.2 hdg exp No. 13, 2012, s 305
s 304 exp No. 13, 2012, s 305
pt 10.3 hdg exp No. 13, 2012, s 305
s 305 exp No. 13, 2012, s 305
sch 1 amd No. 12, 2014, s 31
sch 2 amd No. 27, 2021, s 10
sch 4 exp No. 13, 2012, s 305